AddLife AB (publ) (ALIF-B) fair value: what the stock is really worth
As of Oct 19, 2026: fair value (intrinsic value) of AddLife AB (publ) stock SEK 186, price SEK 185, upside +0.5%, quality 67 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 13, 2026.
How to read this chart
60‑month range kr 54.95 – kr 379.11 · fair‑value band kr 130.14 – kr 241.68 · the kr 185.00 price screens below the kr 185.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 13, 2026.
Follow AddLife AB (publ) in your weekly email
Every Wednesday you see whether AddLife AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
AddLife AB (publ), together with its subsidiaries, provides instruments and equipment, consumables, and reagents primarily to medical care, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in two segments, Labtech and Medtech.
Show moreShow less
The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory analysis.
It offers products and solutions, including analytical instruments, equipment, microscopes, consumables, and reagents, as well as software support and technical services; and in the areas of microbiology, clinical chemistry, coagulation, molecular biology, research, immunology, point-of-care testing, veterinary diagnostics, as well as in the food industry.
This segment also provides training programs for its customers.
The Medtech segment provides medical device products for surgery, orthopaedics, critical care, endoscopy, wound care, healthcare IT, ophthalmology, home adaptation, and technical aids, as well as surgical procedures, welfare technology, and assistive devices for the elderly and disabled.
It operates in Sweden, the United Kingdom, Ireland, Spain, Denmark, Norway, Italy, Finland, Switzerland, Germany, Poland, Austria, rest of Europe, and internationally. AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.
Stock analysis
AddLife AB (publ) (ALIF-B) currently trades at kr 185.00, while our model-based Fair Value estimate is kr 185.90, so the stock looks roughly fairly valued today (gap 0.5%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of kr 154.29 per share, and 6 of the 22 models we run sit above the kr 185.00 price.
Bear case: the Economic Profit group reads lowest at kr 27.73, and 16 of the 22 models stay below the price. Data coverage for this calculation is high.
Scenario range: kr 130.14 (bear) to kr 241.68 (bull), the price of kr 185.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
AddLife AB (publ) reported revenue of 10.4B SEK in FY2025 versus 8.0B SEK in FY2021, a compound +6.9%/yr. Reported net income was 560M SEK in FY2025, compounding −6.1%/yr from FY2021.
Key figures
Market cap 22.5B SEK (≈ $2.3B) Mid · P/E ratio 35.3 · P/S ratio 2.14 · EPS (TTM) kr 4.89 · Dividend yield 0.8% · Net margin 5.7% · Return on equity 10.9% · Return on assets (EBIT) 6.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 45 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 39% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −39% fair-value upside, at 0%, ALIF-B screens cheaper than that median.
Fair Value models
Bearkr 130.14Fair Value kr 185.90Bullkr 241.68
Price kr 185.00 · Upside +0.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (kr 2.72 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.90/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+1.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.6%
Start year 2020 (pandemic). Over 10 years: +20.9% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +2.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.4%
Dividend (yield on the price)0.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.0.0% vs 15.2%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 8%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Rate on operating basis: 2025 sits 122% above its own trend.
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+15.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+6.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +12.8% a year for the price and +4.2% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 184 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score67 · Above median
Fair Value upside+0.5% · Above median
Profitability
Return on equity (12 months)10.9% · Above median
Return on assets4.4% · Above median
Net margin (12 months)5.7% · Below median
Operating margin (12 months)8.7% · Below median
Growth and dividend
Revenue growth (quarter YoY)5.5% · Below median
Dividend yield (12 months)0.8% · Below median
Balance sheet
Debt / equity0.52× · Highest 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)35.3× · Pricier than median
P/B4.14× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "AddLife AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/ALIF-B
Frequently asked questions
Is AddLife AB (publ) (ALIF-B) overvalued or undervalued?
As of Oct 13, 2026, our model estimates a fair value of kr 185.90 versus a price of kr 185.00, about +0% upside (fairly valued).
What is the fair value of ALIF-B?
Our model-based fair value for AddLife AB (publ) is kr 185.90 (as of Oct 13, 2026), built from audited fundamentals. The current price: kr 185.00.
What is the quality score of ALIF-B?
AddLife AB (publ) has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AddLife AB (publ) (ALIF-B)?
Our model-based price target is the fair value of kr 185.90 (as of Oct 13, 2026) from 22 valuation models. Cautious scenario kr 130.14, optimistic scenario kr 241.68. It is a calculation from audited fundamentals, not an analyst target.
What is the AddLife AB (publ) stock forecast for 2026?
Our models put fair value at kr 185.90, about +0% upside versus a price of kr 185.00 (fairly valued). Cautious scenario kr 130.14, optimistic scenario kr 241.68. The calculation is refreshed regularly with new filings.
What is the revenue of AddLife AB (publ) (ALIF-B)?
AddLife AB (publ) reported trailing-twelve-month revenue of about 10.5B SEK (latest available figure, as of Oct 13, 2026).
Does AddLife AB (publ) pay a dividend?
AddLife AB (publ) currently shows a dividend yield of 0.81% relative to its recent price (as of Oct 13, 2026).
What growth is priced into AddLife AB (publ) (ALIF-B)?
For today's price to be fair in a discounted-cash-flow model, AddLife AB (publ) would have to grow free cash flow by +15.1 % per year for five years (discount rate 10.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +14.6 % per year. As of Oct 13, 2026.
What discount rate (WACC) does the fair value of ALIF-B use?
Our models discount AddLife AB (publ) at 10.8 %: a base by market capitalisation (mid), damped by beta 1.55, country premium for Sweden. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For AddLife AB (publ) that is +15.1 % per year a year over ten years, using the same discount rate (10.8 %) and the same formula as our fair value.
How much growth has AddLife AB (publ) (ALIF-B) delivered so far?
Over the past 5 years revenue at AddLife AB (publ) grew +14.6 % a year. The price currently implies +15.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of AddLife AB (publ) (ALIF-B) growing?
The median revenue growth in the sector is +5.6 % a year. That is the yardstick for the growth priced into AddLife AB (publ) (+15.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of AddLife AB (publ) (ALIF-B)?
The free-cash-flow yield on the price is 5.05 %: that much free cash flow AddLife AB (publ) produces per unit of market value. When it exceeds the discount rate of our models (10.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of AddLife AB (publ) (ALIF-B)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AddLife AB (publ) it is kr 185.90 per share (as of Oct 13, 2026), against a price of kr 185.00. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is AddLife AB (publ) stock overvalued or undervalued in 2026?
As of Oct 13, 2026, ALIF-B trades below its calculated fair value: price kr 185.00, fair value kr 185.90, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALIF-B?
No. The price is what the market pays today (kr 185.00); the fair value is what the company's own numbers justify (kr 185.90). For AddLife AB (publ) the two are kr 0.9000 per share apart. That gap is exactly why we show both numbers side by side.
How much is AddLife AB (publ) worth?
The market values AddLife AB (publ) at about 22.5B SEK (market capitalisation, as of Oct 13, 2026). Per share that is kr 185.00; our models calculate a fair value of kr 185.90 per share.
What do the bullish and bearish scenarios say about ALIF-B?
Our models span a range for AddLife AB (publ): cautious scenario kr 130.14, base kr 185.90, optimistic kr 241.68 per share (as of Oct 13, 2026, price kr 185.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ALIF-B?
AddLife AB (publ) trades at a price-to-earnings ratio of 35.3 (as of Oct 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of kr 185.90 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 50.7 (reported for FY2025: 40.3). Other multiples: P/B 4.1, P/S 2.1, EV/EBITDA 17.0.
How solid is the balance sheet of AddLife AB (publ) (ALIF-B)?
Balance-sheet figures for AddLife AB (publ) (as of Oct 13, 2026): return on equity 10.9%, debt of 0.52 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is ALIF-B from its 52-week high?
AddLife AB (publ) trades at kr 185.00, about 10% below its 52-week high of kr 204.67 and 39% above the low of kr 133.22 (as of Oct 19, 2026). Distance from the high says nothing about value: that is what the fair value of kr 185.90 is for.
Which stocks are comparable to AddLife AB (publ)?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AddLife AB (publ) stock attractive at the current price?
The data as of Oct 13, 2026: price kr 185.00, calculated fair value kr 185.90 (+0%), Quality Score 67/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALIF-B calculated?
We run AddLife AB (publ) through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 185.90, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. AddLife AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AddLife AB (publ) (ALIF-B)?
The closing price on Oct 19, 2026 was kr 185.00. Our model-based fair value is kr 185.90, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AddLife AB (publ) right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (kr 130.14 to kr 241.68) leaves room in how you read the outcome.
Where does the earnings growth of AddLife AB (publ) (ALIF-B) come from?
Earnings per share at AddLife AB (publ) grew +10.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +17.6 %, EBIT margin −0.9 %, tax rate −1.7 %, residual (interest, one-offs) −3.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of AddLife AB (publ)
How large is the market capitalisation of AddLife AB (publ) (ALIF-B)?
The market capitalisation of AddLife AB (publ) is 22.5B SEK (≈ $2.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AddLife AB (publ) (ALIF-B)?
The price-to-sales ratio of AddLife AB (publ) is 2.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AddLife AB (publ) (ALIF-B)?
Earnings per share at AddLife AB (publ) are kr 4.89 (price ÷ EPS = P/E 35.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of AddLife AB (publ) (ALIF-B)?
The dividend yield of AddLife AB (publ) is 0.8% (payout 38.6%, on adjusted earnings, reported 30.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of AddLife AB (publ) (ALIF-B)?
The net margin of AddLife AB (publ) is 5.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AddLife AB (publ) (ALIF-B)?
The return on equity (ROE) of AddLife AB (publ) is 10.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AddLife AB (publ) (ALIF-B)?
On an EBIT basis the return on assets of AddLife AB (publ) is 6.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AddLife AB (publ) (ALIF-B)?
The operating margin of AddLife AB (publ) is 8.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AddLife AB (publ) (ALIF-B)?
Revenue at AddLife AB (publ) is growing +5.5% versus a year earlier (3y avg +4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at AddLife AB (publ) (ALIF-B)?
Earnings per share at AddLife AB (publ) are growing +29.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does AddLife AB (publ) (ALIF-B) carry?
The net debt of AddLife AB (publ) is 4.0B SEK (fiscal year 2025, ≈ 3.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch AddLife AB (publ) in the live analysis
One click puts AddLife AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Broad data
Oct 13, 2026